Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE...
October 20, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances...
October 20, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to Present at the LD Micro Main Event XIX

AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative...
October 09, 2025 17:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel...
October 07, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.
October 02, 2025 16:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands...
October 02, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
October 01, 2025 09:20 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel...
September 29, 2025 16:30 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces $2.25 Million Private Placement

CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...
September 26, 2025 09:15 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological...